We are live on ! Find out more
CBPO

China Biologic Products Holdings, Inc.
CBPO

Delisted

CBPO was delisted on the 20th of April, 2021.

0 hedge funds and large institutions have $0 invested in China Biologic Products Holdings, Inc. in 2021 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 84 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 860 (-86)

100% less funds holding in top 10

Funds holding in top 10: 50 (-5)

100% less capital invested

Capital invested by funds: $1.74B → $0 (-$1.74B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 84

Holders
Holders Change
-86
Holders Change %
-100%
% of All Funds
Holding in Top 10
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-100%
% of All Funds
New
Increased
Reduced
Closed
84
Calls
Puts
Net Calls
Net Calls Change

CBPO Hedge Fund Activity: Q2 2021 in Review

0 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q2 2021, worth a combined $0 — down 100% from $1.74B a quarter earlier.

Sellers outnumbered buyers: 84 funds closed out of CBPO and 0 opened new positions — a net loss of 84 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was HHLR Advisors, exiting entirely with an estimated $351M sold.

  • 0 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q2 2021, down from 86 in Q1 2021.
  • Funds reported $0 of China Biologic Products Holdings, Inc. stock for Q2 2021, down 100% quarter-over-quarter.
  • 0 funds opened new China Biologic Products Holdings, Inc. positions in Q2 2021 and 84 closed out, a net change of -84 holders.
  • The largest China Biologic Products Holdings, Inc. seller in Q2 2021 was HHLR Advisors, an estimated $351M sold.

Based on aggregated 13F filings for Q2 2021.